ArticleCancer immunology, immunotherapy : CII2004
Dendritic cells are dysfunctional in patients with operable breast cancer.
Article in Cancer immunology, immunotherapy : CII, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 131 citations in OpenAlex.
- Manufacturing synthetic viscoelastic antigen-presenting cells for immunotherapy.Nature protocols · 2026Review
- Feeder-free generation of functional dendritic cells from human pluripotent stem cells.Journal for immunotherapy of cancer · 2026Article
- Innovative combinatory approaches with dendritic cell-based vaccines: bridging preclinical insights and clinical challenges.Clinical and experimental medicine · 2026Review
- Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines.Experimental hematology & oncology · 2025Review
- The SLC26A4-AS1/NTRK2 axis in breast cancer: insights into the ceRNA network and implications for prognosis and immune microenvironment.Discover oncology · 2025Article
- Subcutaneous biodegradable scaffolds for restimulating the antitumour activity of pre-administered CAR-T cells.Nature biomedical engineering · 2025Article
- Artificial antigen-presenting cells: the booster for the obtaining of functional adoptive cells.Cellular and molecular life sciences : CMLS · 2024Review
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies.Medical oncology (Northwood, London, England) · 2024Review
- Breast Cancer Immunity: It is TIME for the Next Chapter.Cold Spring Harbor perspectives in medicine · 2024Review
- Characterization of CAR T Cells Manufactured Using Genetically Engineered Artificial Antigen Presenting Cells.Cell journal · 2023Article
- Dendritic cell-mimicking scaffolds for ex vivo T cell expansion.Bioactive materials · 2023Article
- Construction of a ferroptosis-based prognostic model for breast cancer helps to discriminate high/low risk groups and treatment priority.Frontiers in immunology · 2023Article
- Dendritic cells transfected with a polyepitope DNA construct stimulate an antitumor cytotoxic response in various tumors.Molecular and clinical oncology · 2022Article
- Nanoparticle-based modulation of CD4Nature communications · 2022Article
- Breast cancer immune microenvironment: from pre-clinical models to clinical therapies.Breast cancer research and treatment · 2022Review
- Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC.Cancer immunology, immunotherapy : CII · 2021Article
- Dendritic Cells Are Associated with Prognosis and Survival in Breast Cancer.Diagnostics (Basel, Switzerland) · 2021Article
- The Peripheral Immune Landscape of Breast Cancer: Clinical Findings and In Vitro Models for Biomarker Discovery.Cancers · 2021Review
- Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy.Biomaterials · 2021Review
- Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications.Frontiers in cell and developmental biology · 2021Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDendritic cells (DCs) play a crucial role in presenting antigens to T lymphocytes and inducing cytotoxic T cells. DCs have been studied in patients with breast cancer to define the factors leading to failure of an effective systemic and locoregional anticancer host response.
methodsPurified DCs were obtained from peripheral blood (PB) and lymph nodes (LNs) of women with operable breast cancer, using immunomagnetic bead selection. The stimulatory capacity of DCs in the allogeneic mixed leukocyte reaction (MLR) and autologous T cell proliferation test (purified protein derivative (PPD) as stimulator), the expression of surface markers on DCs and the production of cytokines in vitro by DCs from patients with operable breast cancer and from healthy donors (controls) were studied.
results70-75% purified DCs were isolated from PB and LNs. PBDCs and LNDCs from patients with operable breast cancer demonstrated a reduced capacity to stimulate in an MLR, compared with PBDCs from normal donors (p<0.01). Autologous T cell proliferation in patients had a decreased ability to respond to PPD, when compared with controls (p<0.01). However, T cells from patients responded as well as control T lymphocytes in the presence of control DCs. PBDCs and LNDCs from patients expressed low levels of HLA-DR and CD86, and induced decreased interleukin-12 (IL-12) secretion in vitro, compared with DCs from normal donors (p<0.01).
conclusionThese data suggest a defective DC function in patients with operable breast cancer. Switched-off DCs in patients with early breast cancer and decreased IL-12 production may be important factors for progressive tumour growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.